Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.
Key Financial Performance
Consolidated revenues $43.4 million, a 21.6% increase from $35.7 million in Q3 2024. The increase was driven by higher sales in the Battery & Energy Products segment and the acquisition of Electrochem.
Battery & Energy Products segment revenues $39.9 million, a 22.8% increase from $32.5 million in Q3 2024. Excluding Electrochem, sales increased by 1.9% year-over-year. Growth in government defense sales (up 19%) was offset by declines in commercial sales (down 5.7%), including a 13.3% drop in oil and gas sales due to macroeconomic and geopolitical factors and a 10.4% decline in medical battery sales due to order timing.
Communications Systems segment revenues $3.4 million, an 8.2% increase from $3.2 million in Q3 2024. The increase was attributed to new product launches.
Consolidated gross profit $9.6 million, a 10.8% increase from $8.7 million in Q3 2024. Gross margin declined by 210 basis points to 22.2% from 24.3% due to manufacturing inefficiencies caused by quality issues with incoming raw materials and components, as well as a less favorable sales mix.
Battery & Energy Products gross profit $8.8 million, a 9.6% increase from $8 million in Q3 2024. Gross margin declined to 22.1% from 24.7% due to quality issues with raw materials and components and a less favorable sales mix.
Communications Systems gross profit $0.8 million, a 33.3% increase from $0.6 million in Q3 2024. Gross margin improved to 23.3% from 20% due to better product mix.
Operating expenses $10.6 million, a 29.4% increase from $8.2 million in Q3 2024. The increase included $1.3 million from the inclusion of Electrochem and $1.1 million in nonrecurring costs, such as the Calgary facility closure and litigation costs.
Operating loss $1 million, compared to an operating income of $0.5 million in Q3 2024. The loss was due to lower gross margins, nonrecurring costs, and delayed sales orders in the Communications Systems segment.
Net loss $1.2 million or $0.07 per share, compared to a net income of $0.3 million or $0.02 per share in Q3 2024. The loss was driven by the operating loss and higher interest expenses.
Adjusted EBITDA $2 million or 4.7% of sales, compared to $1.9 million or 5.4% of sales in Q3 2024. The slight increase was due to higher revenues, offset by lower margins.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Conformal Wearable Battery: Production quantities have begun shipping. Multiple large volume opportunities quoted, mainly for international customers, with expected awards for 2026 deliveries.
High-Capacity Thionyl Chloride D Cell: Passed critical quality audits in China. UL testing and validation expected to complete in Q4, with initial production volume commitments soon after.
XR123A Cells: Received follow-on PEO from a major illumination company. Deliveries to begin in Q4 and continue through the first half of 2026. New battery packs utilizing XR123A cells offer a 30% increase in energy density.
Thin Cell Technology: Initial production capabilities established for medical wearable and item tracking applications. Sales pipeline strengthening with several projects in qualification phase. Additional development efforts underway to reduce thickness and manufacturing complexity.
X5 Medical Car Products: Expanded product family with a portable power bank targeting tablet and portable computers. Production validation and certification nearing completion, with samples sent to key partners for quotations.
Government Defense Sales: Increased 19% year-over-year, driven by strong demand from U.S.-based global prime.
Commercial Sales: Decreased 5.7% due to declines in oil and gas sales (13.3%) and medical battery sales (10.4%) caused by macroeconomic and geopolitical factors.
International Sales: Shifted to 28% of total sales compared to 44% in the prior year, reflecting heightened domestic shipments of government defense products.
Calgary Facility Closure: Facility closure planned with production relocated to Houston. Expected annual savings of $0.8 million starting in 2026.
Electrochem Transition: Transition to Ultralife's information systems completed. Vertical integration opportunities expanded, enabling incorporation of Electrochem cells into existing pack assemblies.
Rebranding Initiative: Company-wide rebranding to emphasize the Ultralife brand, aiming for cohesive marketing, stronger brand equity, and reduced redundancy. First phase targeted for Q4 completion.
New Product Development: Investments in ruggedized server cases, amplifiers, and next-gen communication solutions to expand market share in ruggedized computing and military applications.
Operational Efficiency: Lean productivity projects initiated to improve gross margins. External expertise engaged for process improvements at Newark location.
Vertical Integration: Efforts to qualify Electrochem cells with oil and gas customers to transition battery packs to these cells, with benefits expected in 2026.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Supply Chain Quality Issues: Incoming supply chain quality issues affected product mix and line efficiencies in the Battery & Energy business, leading to gross margin challenges.
Communications Business Performance: The Communications business continues to weigh on earnings as new products are launched and sell-through gains momentum.
Facility Closure Costs: The planned closure of the Calgary location incurred a one-time cost of $0.5 million, with production being relocated to Houston.
Macroeconomic and Geopolitical Factors: Declines in oil and gas sales (13.3%) were attributed to macroeconomic and geopolitical factors.
Medical Battery Sales Decline: Medical battery sales decreased by 10.4% due to the timing of orders.
Operating Expenses Increase: Operating expenses increased by $2.4 million year-over-year, including $1.1 million of nonrecurring costs such as litigation for a cyber insurance claim and transition costs for Electrochem.
Interest Expense and Currency Fluctuations: Other expenses increased due to higher interest expenses on acquisition debt and the impact of foreign currency fluctuations.
Gross Margin Decline: Gross margin declined by 210 basis points year-over-year, primarily due to quality issues with incoming raw materials and components, as well as sales mix changes.
Delayed Sales Orders: Delayed sales orders in the Communications Systems segment contributed to operating losses.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: The company expects to see benefits from qualifying Electrochem cells with several oil and gas customers in 2026. Additionally, large volume opportunities for conformal wearable batteries are expected to result in awards for 2026 deliveries.
Product Development: The company is investing in new product development, including ruggedized server cases, next-gen communication and control solutions, high-performance amplifiers, and thin cell technology for medical wearable sensors. Initial production for several products is expected in 2026.
Operational Efficiency: The closure of the Calgary facility is expected to save approximately $0.8 million annually starting in 2026. Lean productivity projects and process improvements are being implemented to stabilize and improve gross margins.
Market Expansion: The company is targeting international customers for conformal wearable batteries and has received a follow-on purchase order for XR123A cells, with deliveries planned for 2026. The sales pipeline for thin cell technology is strengthening, with several projects in the qualification phase.
Defense Sector: The company has received a $5.2 million BA-53 battery award for delivery throughout 2026. New amplifier and Crescent server products are being developed for military applications, with production expected in 2026.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Were there any questions asked during the Q&A session?
A:No, there were no questions asked during the Q&A session.
Q:Review of Unclear Management Responses
A:There were no questions asked, so management did not avoid answering any questions or provide unclear responses.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Associates Inc
Burfening investor
CEO Philip
Calgary facility
Calgary location
Calgary percentage
Communications product
Defense sale
Electrochem Ultralife
Electrochem closure
Electrochem onetime
Electrochem parent
Electrochem service
Electrochem shipment
Excel acquisition
Government Defense
Heilshorn Associates
Houston facility
Inc Latanya
Instructions conference
Latanya Ultralife
Ultralife brand
Ultralife information
closure Calgary
completion
debt agreement
decline Battery
gas sale
information system
issue material
loss
profitability
quality issue
supply chain
ULBI Transcript
Ultralife Corporation (ULBI) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights strong financial performance with a 12% YoY revenue increase and improved margins, driven by demand in medical and defense sectors. Despite risks like economic conditions and potential military spending cuts, the company's operational efficiency and product mix improvements bolster sentiment. The absence of strategic updates or shareholder return plans limits the positivity, but the solid financials suggest a positive short-term stock reaction.
Ultralife Corporation (ULBI) Q4 2025 Earnings Call Transcript
Unknown3-10
The earnings call highlights a mixed financial performance with strong revenue growth in Battery & Energy Products but significant challenges in Communications Systems. Operational inefficiencies, delays in government contracts, and a net loss due to impairment charges weigh negatively. The Q&A section reveals management's lack of clarity on timelines for key projects, adding uncertainty. Despite some positive aspects like backlog growth and new medical orders, the overall sentiment is negative, especially given the financial losses and strategic risks.
Ultralife Corporation (ULBI) Q3 2025 Earnings Call Transcript
Unknown11-18
The earnings call presented mixed signals: strong revenue growth and new product development were offset by declining margins, increased operating expenses, and net losses. The absence of Q&A questions suggests no immediate analyst concerns, but macroeconomic factors and supply chain issues pose risks. With no clear catalyst for a strong move, the stock is likely to remain neutral in the short term.
Ultralife Corporation (ULBI) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call reveals several concerning aspects: a decline in operating income and net profit, decreased communication systems revenue, and increased operating expenses. The Q&A section highlights risks such as tariffs, cyber attack impacts, and lack of specific guidance on potential opportunities. While there is optimism about future growth, the lack of concrete figures and ongoing challenges contribute to a negative sentiment, likely resulting in a stock price decline.
ULBI Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
